Feature|Videos|January 2, 2025
Final Thoughts
The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Advertisement
Episodes in this series
The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is hope to remove manufacturing bottleneck so patient demand and access can improve.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
Novo Nordisk Stock Reacts to Recent Board Changes
3
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
